HomeCompareJEPQ vs EW

JEPQ vs EW: Dividend Comparison 2026

JEPQ yields 11.47% · EW yields 2.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JEPQ wins by $22.4K in total portfolio value
10 years
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.47%
Share price
$53.77
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.8K
Annual income
$2,269.18
Full JEPQ calculator →
EW
EW
● Live price
2.52%
Share price
$79.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$295.93
Full EW calculator →

Portfolio growth — JEPQ vs EW

📍 JEPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJEPQEW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JEPQ + EW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JEPQ pays
EW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JEPQ
Annual income on $10K today (after 15% tax)
$974.55/yr
After 10yr DRIP, annual income (after tax)
$1,928.80/yr
EW
Annual income on $10K today (after 15% tax)
$213.84/yr
After 10yr DRIP, annual income (after tax)
$251.54/yr
At 15% tax rate, JEPQ beats the other by $1,677.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JEPQ + EW for your $10,000?

JEPQ: 50%EW: 50%
100% EW50/50100% JEPQ
Portfolio after 10yr
$34.6K
Annual income
$1,282.55/yr
Blended yield
3.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EW right now

JEPQ
No analyst data
EW
Analyst Ratings
32
Buy
16
Hold
Consensus: Buy
Price Target
$96.38
+21.2% upside vs current
Range: $87.00 — $110.00
Altman Z
10.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JEPQ buys
0
EW buys
0
No recent congressional trades found for JEPQ or EW in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJEPQEW
Forward yield11.47%2.52%
Annual dividend / share$6.16$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$45.8K$23.4K
Annual income after 10y$2,269.18$295.93
Total dividends collected$17.1K$2.8K
Payment frequencymonthlyquarterly
SectorETFHealthcare

Year-by-year: JEPQ vs EW ($10,000, DRIP)

YearJEPQ PortfolioJEPQ Income/yrEW PortfolioEW Income/yrGap
1← crossover$11,967$1,146.53$10,952$251.57+$1.0KJEPQ
2$14,216$1,268.02$11,976$257.49+$2.2KJEPQ
3$16,774$1,392.20$13,077$263.14+$3.7KJEPQ
4$19,667$1,518.21$14,261$268.55+$5.4KJEPQ
5$22,925$1,645.21$15,533$273.70+$7.4KJEPQ
6$26,578$1,772.40$16,899$278.61+$9.7KJEPQ
7$30,656$1,899.04$18,365$283.28+$12.3KJEPQ
8$35,194$2,024.45$19,938$287.72+$15.3KJEPQ
9$40,228$2,148.01$21,626$291.93+$18.6KJEPQ
10$45,796$2,269.18$23,436$295.93+$22.4KJEPQ

JEPQ vs EW: Complete Analysis 2026

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

EWHealthcare

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Full EW Calculator →
📬

Get this JEPQ vs EW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JEPQ vs JEPIJEPQ vs XYLDJEPQ vs QYLDJEPQ vs SCHDJEPQ vs VYMJEPQ vs OJEPQ vs KOJEPQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.